A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S 1 for treatment of gastric cancer with macroscopic peritoneal metastasis
The prognosis of patients with gastric cancer with peritoneal metastasis is extremely poor. This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S 1 in patients with gastric cancer who had macroscopic peritoneal metastasis.
Cancer